Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24021017 | 0.88 | CDK9 (0.54) | CDK9DYRK1AMEN1KMT2ARECQL | |
| SCHEMBL30310501 | 0.88 | CDK9 (0.54) | CDK9DYRK1AMEN1KMT2ARECQL | |
| SCHEMBL25812916 | 0.84 | CDK9 (0.45) | CDK9DYRK1AMEN1KMT2ARECQL | |
| SCHEMBL23835767 | 0.84 | CDK9 (0.45) | CDK9DYRK1AMEN1KMT2ARECQL | |
| SCHEMBL23836116 | 0.81 | TSHR (0.46) | CDK9DYRK1AMEN1KMT2ARECQL | |
| SCHEMBL25789988 | 0.80 | MMP13 (0.50) | CDK9DYRK1ATSHRMTNR1AMTNR1B | |
| SCHEMBL28882676 | 0.79 | BRPF1 (0.42) | MEN1KMT2AGAAL3MBTL1KDM4E | |
| SCHEMBL30831141 | 0.79 | BRPF1 (0.42) | MEN1KMT2AGAAL3MBTL1KDM4E | |
| SCHEMBL4806969 | 0.78 | HSD17B10 (0.37) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL6650617 | 0.77 | CDK9 (0.46) | CDK9DYRK1AMEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-0944616-B1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-07-18 | — | — | US | disclosed |
| US-6353010-B1 | ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS | DARWIN DISCOVERY, LTD. (GB) | 2002-03-05 | — | — | US | disclosed |
| EP-0944616-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998022460-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | PDE3B, PDE3A, PDE2A | CDK9 896/4885DYRK1A 4556/4885MEN1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.